Can a simple scan reveal hidden heart harm from cancer radiation?
NCT ID NCT05775939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether PET/CT scans can detect heart damage caused by radiation therapy in people with lung or esophageal cancer. About 20 participants will get special heart scans before, during, and after their radiation treatment. The goal is to see if the scans can pick up changes in the heart, which may help doctors monitor and reduce heart problems in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2023
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Provide signed and dated informed consent form * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged \>= 18 * Life expectancy \>= 3 months as assessed by Radiation Oncologist * Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose) * Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer * Planned radiation treatment course for management of lung or esophageal cancer \* Both standard and hypofractionation schedules are permitted Exclusion Criteria: * Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist * Palliative radiation doses defined as 20 Gy in 5 fractions
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- Blood test aims to catch Cancer's return earlier
- Can a new pill boost Immunotherapy's power against advanced tumors?
- Can Direct-to-Abdomen chemotherapy tame GI cancers that spread?
- Can new tracers make many cancers light up on scans?
- Can tumor avatars reveal why cancer hits minorities harder?